IBA, Wilex ink licensing pact

Belgian radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.

Redectane is a radiolabeled antibody detected by PET for the diagnosis of renal cell cancer. It currently is in phase III clinical trials.

IBA also will be responsible for manufacturing Redectane and will pay Wilex an initial fee, milestone payments, and other considerations as part of the agreement.

Related Reading

IBA finalizes acquisition of CIS bio, May 30, 2008

IBA opens U.K. production center, March 14, 2008

IBA posts mixed results for 2007, March 7, 2008

IBA inks French particle-beam therapy deal, February 7, 2008

IBA finalizes proton therapy deal, December 21, 2007

Copyright © 2008 AuntMinnie.com

Page 1 of 435
Next Page